New approaches to the endocrine prevention and treatment of breast cancer.
dc.contributor.author | Howell, Anthony | |
dc.contributor.author | Howell, Sacha J | |
dc.contributor.author | Evans, D Gareth R | |
dc.date.accessioned | 2009-08-27T08:21:41Z | |
dc.date.available | 2009-08-27T08:21:41Z | |
dc.date.issued | 2003-07 | |
dc.identifier.citation | New approaches to the endocrine prevention and treatment of breast cancer. 2003, 52 Suppl 1:S39-44 Cancer Chemother. Pharmacol. | en |
dc.identifier.issn | 0344-5704 | |
dc.identifier.pmid | 12819938 | |
dc.identifier.doi | 10.1007/s00280-003-0645-5 | |
dc.identifier.uri | http://hdl.handle.net/10541/78794 | |
dc.description.abstract | All major endocrine prevention approaches act via the estrogen receptor (ER). A simple hypothesis concerning ER expression and breast cancer risk is outlined. We review breast cancer prevention trials with tamoxifen, raloxifene, aromatase inhibitors, and ovarian suppression. Current and planned endocrine prevention trials in populations of pre- and postmenopausal women at risk of breast cancer are summarized and endocrine therapy after primary surgery and for advanced disease discussed. | |
dc.language.iso | en | en |
dc.subject | Breast Cancer | en |
dc.subject.mesh | Breast Neoplasms | |
dc.subject.mesh | Clinical Trials as Topic | |
dc.subject.mesh | Female | |
dc.subject.mesh | Humans | |
dc.subject.mesh | Raloxifene | |
dc.subject.mesh | Receptors, Estrogen | |
dc.subject.mesh | Risk | |
dc.subject.mesh | Selective Estrogen Receptor Modulators | |
dc.subject.mesh | Tamoxifen | |
dc.subject.mesh | Treatment Outcome | |
dc.title | New approaches to the endocrine prevention and treatment of breast cancer. | en |
dc.type | Article | en |
dc.contributor.department | CRUK Department of Medical Oncology, Christie Hospital NHS Trust, University of Manchester, Wilmslow Road, M20 4BX, Manchester, UK. maria.parker@christie-tr.nwest.nhs.uk | en |
dc.identifier.journal | Cancer Chemotherapy and Pharmacology | en |
html.description.abstract | All major endocrine prevention approaches act via the estrogen receptor (ER). A simple hypothesis concerning ER expression and breast cancer risk is outlined. We review breast cancer prevention trials with tamoxifen, raloxifene, aromatase inhibitors, and ovarian suppression. Current and planned endocrine prevention trials in populations of pre- and postmenopausal women at risk of breast cancer are summarized and endocrine therapy after primary surgery and for advanced disease discussed. |